Skip to main content

Table 2 Application of PD-L1 carried by TEXs in evaluation drug resistance and tack prognosis

From: The roles of exosomal immune checkpoint proteins in tumors

Cancer Expression of PD-L1 carried by TEXs Effect Material Sample References
HNSCC Disease progression PB 40 HNSCC patients [52]
PDAC  +  Shorter postoperative survival time PB 55 PDAC patients [58]
Melanoma Respond to treatment PB 18 melanoma patients [63]
NSCLC Respond to treatment PB 8 NSCLC patients [63]
Metastatic melanoma Distinguish melanoma patients from healthy donors PB Patients with stage III to IV melanoma and healthy donors [57]
Melanoma Fail to respond to the anti-PD-1 treatment PB Melanoma patients [57]
Melanoma T cell re-invigoration PB Melanoma patients on pembrolizumab therapy within 6 weeks [57]
Glioblastoma Larger glioblastoma tumor volume PB 21 glioblastoma patients [56]
  1. “↑” Increased, “↓” Decreased, “+” Positive, TEXs tumor-derived exosomes, PD-L1 programmed death ligand 1, HNSCC head and neck squamous cell carcinoma, PB peripheral blood, PDAC pancreatic ductal adenocarcinoma, NSCLC non-small-cell lung cancer, anti-PD-1 anti-programmed death 1